GlobeNewsWire
17 Dec 2025, 13:31 UTC · 40w ago
Verdict
Headline takes no side. We score MBRX +1.00 — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced positive Phase 1 clinical trial results for WP1066, demonstrating safety and efficacy in treating pediatric brain tumors.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
−87.9%
Price is moving against the score
$0.5677 vs $4.69 close before publication (Dec 16) · not market-adjusted
MBRX chart →
